405 related articles for article (PubMed ID: 6572738)
1. Blocking of cell-mediated immunity to Moloney murine sarcoma virus-transformed cells by lactate dehydrogenase virus-antibody complex.
McDonald TL
J Natl Cancer Inst; 1983 Mar; 70(3):493-7. PubMed ID: 6572738
[TBL] [Abstract][Full Text] [Related]
2. Antibody classes and subclasses in circulating immune complexes isolated from mice infected with lactic dehydrogenase virus.
McDonald TL; Donnelly T; Weber A; Quenette L
Immunology; 1983 Mar; 48(3):511-7. PubMed ID: 6826202
[TBL] [Abstract][Full Text] [Related]
3. Non-T-cell-mediated cytotoxicity in mice with tumors induced by Moloney murine sarcoma virus (M-MuSV). II. Granulocyte-mediatd cytotoxicity against autochthonous target cells isolated from M-MuSV-induced tumors.
Becker S; Haskill S
J Natl Cancer Inst; 1980 Aug; 65(2):469-75. PubMed ID: 6249952
[TBL] [Abstract][Full Text] [Related]
4. Secondary in vitro generation of cytolytic T-lymphocytes (CTL's) in the murine sarcoma virus system. Virus-specific CTL induction across the H-2 barrier.
Collavo D; Parenti A; Biasi G; Chieco-Bianchi L; Colombatti A
J Natl Cancer Inst; 1978 Sep; 61(3):885-90. PubMed ID: 80457
[TBL] [Abstract][Full Text] [Related]
5. Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotypic antibody as immunogen.
Powell TJ; Spann R; Nguyenduc M; Lamon EW
J Immunol; 1989 Feb; 142(4):1318-24. PubMed ID: 2536772
[TBL] [Abstract][Full Text] [Related]
6. Lactate dehydrogenase-elevating virus (LDV): lifelong coexistence of virus and LDV-specific immunity.
van den Broek MF; Spörri R; Even C; Plagemann PG; Hänseler E; Hengartner H; Zinkernagel RM
J Immunol; 1997 Aug; 159(4):1585-8. PubMed ID: 9257815
[TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin transfer from immune-reconstituted SCID mice to nursing neonates: blood distribution of antibody and association with perinatal virus protection.
Broen JJ; Cafruny WA
Reg Immunol; 1993; 5(1):44-52. PubMed ID: 8347469
[TBL] [Abstract][Full Text] [Related]
8. Augmented immunogenicity of tumor cell membranes produced by infection with influenza virus as compared to Moloney sarcoma virus.
Takeichi N; Austin FC; Oikawa T; Boone CW
Cancer Res; 1978 Dec; 38(12):4580-4. PubMed ID: 214226
[TBL] [Abstract][Full Text] [Related]
9. Transplacental lactate dehydrogenase-elevating virus (LDV) transmission: immune inhibition of umbilical cord infection, and correlation of fetal virus susceptibility with development of F4/80 antigen expression.
Zitterkopf NL; Haven TR; Huela M; Bradley DS; Cafruny WA
Placenta; 2002 May; 23(5):438-46. PubMed ID: 12061860
[TBL] [Abstract][Full Text] [Related]
10. Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: activity of IgM and IgG with specificity for MLV determined antigen(s).
Lamon EW; Skurzak HM; Andersson B; Whitten HD; Klein E
J Immunol; 1975 Apr; 114(4):1171-6. PubMed ID: 1117138
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immunity to Moloney sarcoma virus in mice. II. Analysis of antigenic specificities involved in T lymphocyte-mediated in vivo rejection of murine sarcoma virus-induced tumors.
Gorczynski RM; Knight RA
Eur J Immunol; 1975 Feb; 5(2):148-55. PubMed ID: 1086221
[TBL] [Abstract][Full Text] [Related]
12. T lymphocyte tolerance and early appearance of virus-induced cell surface antigens in Moloney-murine leukemia virus neonatally injected mice.
Collavo D; Zanovello P; Biasi G; Chieco-Bianchi L
J Immunol; 1981 Jan; 126(1):187-93. PubMed ID: 6969741
[TBL] [Abstract][Full Text] [Related]
13. Immune responses in mice infected with lactic dehydrogenase virus. I. Antibody response to DNP-BGG and hyperglobulinaemia in BALB/c mice.
Michaelides MC; Simms ES
Immunology; 1977 Jun; 32(6):981-8. PubMed ID: 885591
[TBL] [Abstract][Full Text] [Related]
14. Effect of lactic dehydrogenase virus infection on tumor induction and tumor growth.
Isakov N; Feldman M; Segal S
Cancer Res; 1981 Feb; 41(2):667-72. PubMed ID: 7448812
[TBL] [Abstract][Full Text] [Related]
15. Neonatal infection of mice with lactate dehydrogenase-elevating virus results in suppression of humoral antiviral immune response but does not alter the course of viraemia or the polyclonal activation of B cells and immune complex formation.
Rowland RR; Even C; Anderson GW; Chen Z; Hu B; Plagemann PG
J Gen Virol; 1994 May; 75 ( Pt 5)():1071-81. PubMed ID: 8176369
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of experimental tumors in mice by treatment with concanavalin A.
Ekstedt RD
J Natl Cancer Inst; 1979 Oct; 63(4):1065-9. PubMed ID: 480379
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal IgM antibodies that inhibit primary Moloney murine sarcoma growth.
Lamon EW; Powell TJ; Walia AS; Lidin BI; Srinivas RV; Baskin JG; Kearney JF
J Natl Cancer Inst; 1987 Mar; 78(3):547-56. PubMed ID: 3469466
[TBL] [Abstract][Full Text] [Related]
18. Lactate dehydrogenase-elevating virus induces anti-Golgi apparatus antibodies.
Weiland E; Weiland F; Grossmann A
J Gen Virol; 1987 Jul; 68 ( Pt 7)():1983-91. PubMed ID: 3598563
[TBL] [Abstract][Full Text] [Related]
19. Antibody production and interaction with lymphoid cells in relation to tumor immunity in the Moloney sarcoma virus system.
Harada M; Pearson G; Redmon L; Winters E; Kasuga S
J Immunol; 1975 Apr; 114(4):1318-22. PubMed ID: 1090675
[TBL] [Abstract][Full Text] [Related]
20. Tumor sponge implantation: an in vivo method for studying syngeneic, primary antitumor lymphocyte responses.
Vallera DA; Mentzer SJ; Maizel SE
Cancer Res; 1982 Feb; 42(2):397-404. PubMed ID: 7055792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
